REVANCE THERAPEUTICS INC's ticker is RVNC and the CUSIP is 761330109. A total of 159 filers reported holding REVANCE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 2.29 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $341,255 | -25.4% | 13,483 | -5.0% | 0.00% | 0.0% |
Q1 2023 | $457,382 | +69.4% | 14,200 | +46.5% | 0.00% | 0.0% |
Q3 2021 | $270,000 | -5.9% | 9,691 | 0.0% | 0.00% | – |
Q2 2021 | $287,000 | -36.6% | 9,691 | -40.2% | 0.00% | -100.0% |
Q1 2021 | $453,000 | -9.2% | 16,208 | -7.9% | 0.00% | 0.0% |
Q4 2020 | $499,000 | -1.4% | 17,594 | -12.6% | 0.00% | 0.0% |
Q3 2020 | $506,000 | +55.7% | 20,141 | +51.4% | 0.00% | 0.0% |
Q2 2020 | $325,000 | +61.7% | 13,303 | +64.5% | 0.00% | – |
Q3 2018 | $201,000 | -44.8% | 8,086 | -39.0% | 0.00% | – |
Q2 2018 | $364,000 | -10.6% | 13,249 | +0.3% | 0.00% | – |
Q1 2018 | $407,000 | -11.5% | 13,210 | +2.8% | 0.00% | – |
Q4 2017 | $460,000 | +60.8% | 12,854 | +23.7% | 0.00% | – |
Q3 2017 | $286,000 | +74.4% | 10,391 | -13.9% | 0.00% | – |
Q2 2016 | $164,000 | -38.1% | 12,073 | -20.5% | 0.00% | – |
Q1 2016 | $265,000 | -38.1% | 15,187 | +21.3% | 0.00% | -100.0% |
Q4 2015 | $428,000 | – | 12,521 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
NovaQuest Capital Management, L.L.C. | 1,558,426 | $48,000,000 | 65.50% |
Essex Woodlands Management, Inc. | 3,842,047 | $118,335,000 | 25.90% |
Rhenman & Partners Asset Management AB | 203,181 | $6,258,000 | 0.77% |
EAM Global Investors LLC | 44,898 | $1,383,000 | 0.72% |
Fosun International Ltd | 319,313 | $9,835,000 | 0.62% |
EAM Investors, LLC | 113,096 | $3,483,000 | 0.58% |
ArrowMark Colorado Holdings LLC | 1,735,699 | $53,460,000 | 0.53% |
Perceptive Advisors | 618,957 | $19,064,000 | 0.53% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 111,360 | $3,430,000 | 0.45% |
Schonfeld Strategic Advisors LLC | 83,700 | $2,578,000 | 0.19% |